Suche
Mein Konto
FPÖ warns: Government hands over health policy to WHO!
The FPÖ is discussing the WHO and ivermectin in parliament, criticizing the federal government and calling for more personal responsibility.
FPÖ warns: Government hands over health policy to WHO!
On July 9, 2025, the FPÖ discussed an amendment to the WHO's International Health Regulations (IHR) in parliament. The FPÖ petition spokeswoman NAbg said: Marie-Christine Giuliani-Sperrer criticizes unqualified statements about Ivermectin, a drug whose developers received the Nobel Prize. She emphasized the importance of dosage for the effectiveness of medicines and expressed concerns about the government's communication regarding the corona vaccination and its possible side effects.
Giuliani-Sperrerer called for more personal responsibility and honest information for the population and criticized the government for giving further powers to the WHO. In this context, the SPÖ health minister was described as technically inadequate because she came from the union. In addition, Giuliani-Sperrer warned of possible conflicts of interest from pharmaceutical industry lobbyists and questioned why Austria was adopting the IGV change without resistance while other countries waited.
The situation surrounding ivermectin
Current evidence on the use of ivermectin to treat COVID-19 patients has been assessed as inconclusive by the WHO. [WWHO] recommends that the drug only be used in clinical trials. This applies to both COVID-19 patients with mild and severe symptoms. Ivermectin is a proven antiparasitic agent and is on the WHO list of essential medicines for various parasitic diseases.
The WHO has convened an expert group to address the increased international attention on ivermectin. This group reviewed data from 16 randomized controlled trials involving 2,407 patients and found that the evidence for ivermectin's effectiveness in COVID-19 is of "very low certainty." This is due to the small size and methodological limitations of the studies. WHO recommendations also include that the use of therapeutic agents such as systemic corticosteroids and low-dose anticoagulants is recommended in certain situations, while other medications such as hydroxychloroquine or lopinavir/ritonavir are discouraged.
Warnings and Concerns About Ivermectin
The Federal Office for Safety in Health Care (BASG) already warned against the use of ivermectin to treat COVID-19 in March 2021, and this warning remains in effect. According to [Gesundheit.gv.at], the European Medicines Agency (EMA) also expresses concerns about the use of ivermectin for COVID-19. In Austria, Ivermectin is approved for many animal species to combat internal and external parasites.
In humans, it is used to treat scabies and parasitic worms. Clinical trials have shown inconsistent results, with some indicating no benefit and others indicating possible benefit. The EMA has repeatedly stated that the use of ivermectin cannot be recommended outside of controlled clinical trials. Risks of serious side effects have also been identified at doses higher than those approved.
Virologist Christoph Steininger warns against using ivermectin to treat COVID-19 because it is classified as risky due to the lack of approval and evidence of effectiveness. Controlled drug discovery is crucial for the development of new or improved medicines and must not be undermined.